Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.70
0.00 (0.00%)
At close: Mar 10, 2026
28.09%
Market Cap 1.10B
Revenue (ttm) 163.65M
Net Income (ttm) -85.51M
Shares Out 193.85M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 3,780
Open n/a
Previous Close 5.70
Day's Range n/a
52-Week Range 4.00 - 8.40
Beta -1.23
RSI 6.57
Earnings Date Mar 27, 2026

About Wuhan YZY Biopharma

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 106
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2496
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.